https://www.optimumcomms.com/wp-content/uploads/2026/07/Genopo-logo-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-07-14 14:08:462026-07-14 14:11:21Genopore appoints Rey Mali as Chief Executive Officer to accelerate growth of the pioneering protein identification company
https://www.optimumcomms.com/wp-content/uploads/2026/07/Genopo-logo-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-07-14 14:08:462026-07-14 14:11:21Genopore appoints Rey Mali as Chief Executive Officer to accelerate growth of the pioneering protein identification company
Nucleome Therapeutics strengthens global IP portfolio with US patent for core MCC Technology
Nucleome’s advance in precision and scale of 3D genomics has…

ViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its Board
Ian Wells, former Global Chief Financial Officer of HOYA…

Poolbeg Pharma Plc – Placing to raise £3.5 million, Executive Chair Cathal Friel subscribes for £250,000
Poolbeg Pharma Plc (AIM: POLB), a clinical-stage biopharmaceutical…

Poolbeg Pharma plc – First Patient Dosed in the POLB 001 TOPICAL Clinical Trial
Interim data remains on track for summer 2026 and partnering…

Sofinnova Partners appoints David Evans as Partner
Sofinnova strengthens its growth strategy with a high-caliber…

No easy answers: European research consortia take on major challenges
Nine new Challenge Programme grants from the Novo Nordisk Foundation…

Hansa Biopharma to host Q2 2026 interim results conference call
Lund, Sweden, 8 July, 2026. Hansa Biopharma, “Hansa” (Nasdaq…

AMSilk and Ajinomoto Foods Europe Expand Partnership to Enable Industrial-Scale Production of Silk Proteins
Neuried/Nesle, 8 July 2026 - AMSilk, a global leader in biotech…

Xeltis makes first commercial implant of aXess™, its vascular access device for hemodialysis
Marks start of European commercial rollout of aXess™, bringing…

Sofinnova Partners announces Myricx Bio agrees to be acquired by Novartis
Sofinnova Partners co-led the seed investment in 2019 and…

Hansa Biopharma participating in Wedbush PacGrow Renal Summit
Lund, Sweden, July 2, 2026. Hansa Biopharma AB, “Hansa”…

Xeltis exceeds 50% enrollment in US Pivotal trial for aXess™, its vascular access device for hemodialysis
US pivotal trial is a multi-center study evaluating a bioabsorbable…

CONNECTA Therapeutics and Centre for Genomic Regulation to Present First-in-Class Program CTH120 for Fragile X Syndrome at FENS Forum 2026
Preclinical data highlight restoration of cognitive, behavioral…

Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA
SERB assumes responsibility for the commercialization of…

R1 Therapeutics establishes world-class Scientific Advisory Board to support advancement of AP306 in Chronic Kidney Disease
Seven internationally recognized nephrology experts join…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York